Company intelligence / Profile preview

FermaVir Pharmaceuticals

New York, United States

Ownership: Private
Development stage: Other

Overview

Preclinical-stage antiviral programs including FV-100 (prodrug of CF-1743) for herpes zoster (shingles), demonstrating high potency in vitro, and a series of nucleoside/non-nucleoside analogues for CMV; FV-100 expected to enter Phase I in 2007 but company acquired prior to advancement.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on FermaVir Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FermaVir Pharmaceuticals.

Explore the full profile